Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

ABSTRACT:

Background

Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.

Methods

We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here.

Results

The median progression-free survival was 11.5

SUBMITTER: Larkin J 

PROVIDER: S-EPMC5698905 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature